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T he diagnosis of mantle cell lymphoma (MCL) is established according to the criteria of the World Health Organization classifıcation of hematologic neoplasms. In general, histologic confırmation of diagnosis is mandatory and a lymph node biopsy is strongly recommended; in contrast, lymph node fıne-needle biopsy is not appropriate. A bone marrow aspiration complemented by flow cytometry are mandatory to quantify the percentage of infıltration and optionally identify the pathognomonic t (11;14) by fluorescence in situ hybridization. 1 Most tumors have a classic morphology of small to medium sized cells with irregular nuclei, dense chromatin, and unapparent nucleoli. In addition, a blastoid variant of the disease has been described, characterized by high mitotic rate and particularly aggressive behavior, which is associated with INK4a/ARF deletions and TP53 mutations ( Fig. 1) . However, tumor cells may present with a spectrum of morphologic variants, raising some diffıculties in the differential diagnosis apart from chronic lymphocytic leukemia, marginal zone lymphomas, large B-cell lymphomas, or blastic hematologic proliferations.
Besides the classical immunophenotype (immunoglobulin M/D, CD19, CD20, CD22, CD43, CD79a, CD5 positive, and CD23, CD10, CD200, BCL6 usually negative), the detection of cyclin D1 overexpression (immunohistochemistry) or the chromosomal translocation t (11;14) by fluorescence in situ hybridization is mandatory, since histomorphologic phenotypes may differ signifıcantly. Nevertheless, rare cases of cyclin D1-negative variant of MCL have been recognized, characterized by the same gene expression profıle and secondary genomic alterations as classical MCL. 2 SOX11, a transcription factor expressed in 90% of MCL, might be helpful to identify these cyclin D1-negative variants.
Moreover, Ki67 proliferative index staining is strongly recommended as a powerful prognostic indicator of long-term outcome. 3 
CLINICAL PRESENTATION AND PROGNOSTIC FACTORS
To defıne the stage of MCL, a computed tomography (CT) scan with iodine contrast of the neck, chest, abdomen, and pelvis is mandatory. PET scan is not included in the consensus recommendations, as a large majority of patients present with an advanced stage III to IV MCL because of frequent bone marrow and/or gastrointestinal involvement. Thus, only in the rare stage I to II patients may PET scan be applied to confırm early-stage disease and guide localized treatment. Similarly, endoscopy, based on up to 60% asymptomatic infıltration of the bowel, is recommended only in limited-stage or symptomatic patients. Cerebrospinal fluid evaluation is not usually required at fırst presentation, unless neurologic symptoms are present.
A specifıc prognostic score, the MCL International Prognostic Index (MIPI), allows one to discriminate three prognostic subgroups: the low-risk group with a 5-year median overall survival (OS) of 60%, and the intermediate-and the high-risk group with a median OS of 51 and 29 months, respectively. 4 This score takes into account four parameters (age, performance status, lactate dehydrogenase [LDH] , and leukocyte count) was confırmed also in a simplifıed version. Since MIPI is highly applicable and has been validated in most independent series, its use should be routinely applied in clinical practice. 3 
TREATMENT Indolent Mantle Cell Lymphoma
Although most patients with MCL follow an aggressive clinical course associated with rapid progression and a high recurrence rate, a minority of MCL cases (10% to 15%) will have an indolent behavior and may not need therapy for several years; a delayed treatment did not affect the OS in this low-risk group. 5 Most of these patients present with normal serum LDH level, splenomegaly, bone marrow and blood involvement, but without major adenopathy. The individual diagnosis of such an indolent subtype is diffıcult, but a short observation period may be applied in the majority of lowburden patients.
Molecularly, indolent MCLs predominantly display hypermutated immunoglobulin genes, noncomplex karyotypes, and a peculiar gene expression profıle. In contrast, the role of transcription factor SOX11 expression alone is not suffıcient to predict prognosis. 3, 6, 7 
Elderly Patients
Based on a median age of 65 years at fırst diagnosis, the majority of patients does not qualify for dose-intensifıed regimens. The standard of care for elderly MCL patients consists of combined immunochemotherapy (rituximabbendamustine [BR], R-CHOP; Table 1 ). 8 The European MCL Network conducted an international phase III trial comparing R-CHOP with rituximab, fludarabine, and cyclophosphan (R-FC) followed by a second maintenance randomization with either IFN-␣ or rituximab) in elderly patients. 9 Unexpectedly, the outcome of the fludarabine-containing regimen was disappointing: although complete response (CR) rates after R-FC and R-CHOP were comparable (40% vs. 34%, p ϭ 0.10), progressive disease was more frequent during R-FC (14% vs. 5%). The median OS was also signifıcantly inferior after R-FC (4-year survival rate, 47% vs. 62%, p ϭ 0.005) and more patients in the fludarabine arm died as a result of relapsed lymphoma or infections. This inferior outcome after R-FC is mostly due to long-lasting hematologic grade 3 to 4 toxicity. Thus, the use of upfront R-FC in elderly MCL patients is discouraged. In contrast, rituximab maintenance reduced the risk of progression or death by 45% (58% patients in remission after 4 years vs. 29% with IFN-␣, p ϭ 0.01), almost doubled duration of remission, and signifıcantly improved OS among patients responsive to R-CHOP. Thus, rituximab maintenance (one dose every 2 months) should be offered to all patients responding to R-chemotherapy, especially R-CHOP. 3 Promising data have been also achieved by radioimmunotherapy
KEY POINTS
⅐ Detection of cyclin D1 overexpression or t(11;14) is crucial for the correct diagnosis. ⅐ Cell proliferation (Ki-67) and MIPI are established prognostic markers and should be applied in clinical routine. ⅐ Standard of care in younger patients is a cytarabinecontaining dose-intensified regimen (R-CHOP/R-DHAP followed by autologous stem cell transplantation and Hyper-CVAD). ⅐ In elderly patients a combined immunochemotherapy (BR, R-CHOP) followed by rituximab maintenance should be applied. ⅐ Molecular approaches (bortezomib, ibrutinib, temsirolimus
[an mTOR inhibitor registered in Europe], lenalidomide) should be considered in relapsed disease.
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FIG 1. Molecular pathogenesis (modified from Jares et al. 43 ).
(RIT) consolidation. Four cycles of R-CHOP followed by RIT consolidation compared favorably with historic results of six cycles of R-CHOP. 10 Notably, in a randomized fırst-line trial with 94 MCL patients, the BR schedule was at least as effective as R-CHOP (median PFS 35 vs. 22 months, p ϭ 0.004), and fewer toxic effects (neutropenia, infections, polyneuropathy, and alopecia) were observed, but OS was comparable in both study arms. 11 Thus, specifıcally in patients with comorbidities, BR may be preferred.
The combination with cytarabine (R-BAC) has been recently achieved excellent results in primary and relapsed MCL (90% overall response rate [ORR], CR 83%), resulting in an excellent 2-year progression-free survival (PFS) of 70% and 95% in relapsed and fırst-line patients, respectively. 12 However, a high rate of hematotoxicity has been observed; thus, only very fıt patients prequalify for such an approach.
Based on the excellent results of cytarabine in younger MCL patients, the MCL R2 Elderly trial randomly assigns patients to a standard induction with R-CHOP versus an alternating R-CHOP/R-HAD (rituximab, intermediate ageadjusted dose cytarabine, and dexamethasone) arm.
A rational algorithm for clinical management of MCL patients is presented in Fig. 2 .
Younger Patients
Although no curative treatment is available for MCL so far, an intensive approach, for example, by an autologous stem cell transplant (SCT) has been demonstrated to induce higher response and survival rates in young and fıt patients. Thus, in CHOP-responding patients, a consolidation with total-body irradiation (TBI), high-dose cyclophosphamide, and autologous SCT resulted in longer median PFS (39 vs. 17 months, p ϭ 0.011) compared to a maintenance therapy with IFN-␣. 13 In a subsequent meta-analysis OS was also superior in the autologous SCT arm independent of the addition of rituximab. 14 Such high-dose consolidation can be safely delivered in younger fıt patients usually up to age 65.
The trials of the last decade established the role of a highdose cytarabine-containing induction before an autologous SCT (Table 2) . 15 Based on several phase II studies, the recent European MCL Younger trial confırmed that an alternating induction of three courses of R-CHOP and rituximab, dexamethasone, cytarabine, and cisplatin (R-DHAP) followed by myeloablative consolidation and subsequent autologous SCT achieved a signifıcantly improved median time to treatment failure (TTF; 88 vs. 46 months, p ϭ 0.038) and a trend for median OS (not reached vs. 83 months, p ϭ 0.045) in comparison to an R-CHOP only induction followed by autolo- gous SCT. 16 Even more impressive, the rate of molecular remission increased from 32% to 73% after induction. In contrast, an induction based on high-dose cytarabine achieves only insuffıcient response rates. 17 The applied conditioning regimens before autologous SCT are mainly BEAM or TBI-based. A retrospective European Group for Blood and Marrow Transplantation (EBMT) register study of more than 400 patients suggested that TBI may benefıt especially the PR patients after induction. In a retrospective study comparison of the Nordic, HOVON, and MCL Younger protocols, TBI was confırmed to be benefıcial only in patients in partial remission. 18 Taken together, these studies suggest that TBI should be strongly considered in patients in PR. In contrast, the benefıt of RIT has not been demonstrated in interstudy comparisons.
Besides autologous SCT-based regimens, another doseintensifıed approach (R-Hyper-CVAD) with alternating R-CHOP-like and high-dose methotrexate/cytarabine cycles also achieved very high response and survival rates in a mono-center study (ORR 97%, CR 87%, and median TTF 4.6 years in patients younger than age 65). 19 The high response rates and prolonged duration of remission have been confırmed in multicenter approaches; 20, 21 however, this regimen is hampered by a signifıcant therapy-associated toxicity, so that a signifıcant subset of patients was not able to complete the scheduled therapy (39%-63%).
As no plateau in PFS curves has been observed even after such optimized treatments, and the achievement of molecular remission seems to be critical in MCL, the randomized LyMa trial investigates the role of rituximab maintenance after autologous transplantation. 22 
Allogenic Stem Cell Transplantation
The approach of allogeneic SCT in MCL emerged in the late 1990s, based on the cure of some relapsed/refractory patients with MCL. 23 Reduced-intensity conditioning regimens (RIC-allo) with lower toxicity and reduced transplantrelated mortality provided better long-term results. However, in none of these studies has allogeneic SCT been proven superior to autologous SCT. 24 Thus, the current literature does not support its application in the fırst-line treatment of MCL. Whether an allogeneic SCT consolidation in fırst CR could be benefıcial in very high-risk patients (blastoid variant, elevated Ki-67) is an intriguing hypothesis that has to be addressed in prospective trials.
FIG 2. Therapeutic algorithm.

Patients with Relapsed or Refractory Disease
Among younger patients, an autologous SCT approach should be offered only to those who did not receive an appropriate fırst-line therapy. On the other hand, allogeneic SCT, despite its high treatment-related mortality and relapse rates, remains the only curative approach in relapsed MCL and should be discussed in young fıt patients relapsing after autologous SCT. Specifıcally, a nonmyeloablative approach without T-depletion is advisable, as this modifıcation is also applicable in older patients. 25, 26 In younger patients without a human leukocyte antigen-matched donor, a haploidentical transplantation has achieved promising results in recent studies but is still experimental. 27 Numerous targeted options in combination with rituximabsupplemented chemotherapy represent highly effective approaches in elderly patients. 28 Second-line therapy should be adapted to the age and performance status of the patient. In fıt patients non-cross-resistant drugs should be preferred as salvage treatment. Thus, after R-CHOP in fırst line, regimens containing rituximab, cytarabine, and/or bendamustineif possible in combination with a molecular approach such as bortezomib, lenalidomide, or temsirolimus (an mTOR inhibitor registered in Europe)-may be considered (Table 3). [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] Trials combining the proteasome inhibitor with R-CHOP; a doxorubicin, dexamethasone, chlorambucil, and rituximab regimen (RiPADϩC); or high-dose cytarabine regimens showed promising results. [29] [30] [31] [32] A tailored therapy concept, based on individual risk profıle, may favor a cytarabine-based approach plus bortezomib or combined with bendamustine for fıt patients with elevated Ki67 levels, whereas a bendamustine-based regimen in combination with temsirolimus or lenalidomide appears more suitable for elderly patients with a more indolent presentation. 36, 37 However, as these recommendations on tailored therapies are not evidence based, an enrollment of these patients in clinical trials is highly recommended.
On the other hand, in impaired patients or subsequent relapses, monotherapies with targeted drugs (in particular, bortezomib, ibrutinib, temsirolimus, or lenalidomide), as well as well tolerable combinations with rituximab, steroids, or low-dose chemotherapy and palliative radiotherapy should be considered. 29, [33] [34] [35] [37] [38] [39] Oral palliative combinations, such as the metronomic PEP-C, could be also useful options in this setting.
Unfortunately, survival curves do not display any plateau in patients in relapse, and almost all patients will fınally relapse. Limited data are available on rituximab maintenance Only studies accounting for more than 40 patients are displayed. Abbreviations: ORR, overall response rate; CR, complete response; PFS, progression-free survival; OS, overall survival; R, rituximab; CHOP, cyclophosphamide/doxorubicin/vincristine/prednisone; TBI, total body irradiation; ASCT, autologous stem cell transplantation; DHAP, dexamethasone/cytarabine/cisplatin; HD-araC, high-dose cytarabine; HyperCVAD, hyperfractionated cyclophosphamide/vincristine/doxorubicin/dexamethasone ϩ methotrexate/cytarabine; NR, not reached; na, not available; ne, not evaluable.
in patients in relapse, and data of RIT consolidation are based on smaller series. The manageable toxicity and oral formulation of lenalidomide, along with its effıcacy, make this drug also an attractive option in the context of maintenance regimens, either alone or in combination with rituximab. [33] [34] [35] In addition, despite some concerns about its cumulative neurotoxicity, bortezomib maintenance is currently tested in young patients after autologous SCT. 
Innovative Molecular Targeted Approaches
The growing insights into the molecular biology of MCL led to the systematic exploration of targeted approaches. 28 Many new compounds have been tested in relapsed MCL (Table 3 ). Bruton's tyrosine kinase (BTK) is an essential component of the B-cell-receptor signaling pathway; its covalent oral inhibitor ibrutinib showed durable single-agent effıcacy in relapsed or refractory MCL. 39 The impressive data from an international phase II trial on heavily pretreated MCL patients described great effıcacy and excellent tolerability: ORR was 68% (21% CR) with a median duration of response of 17.5 months and a median PFS of 13.9 months. Moreover, the most common adverse events were mild or moderate diarrhea, fatigue, and nausea. Grade 3 or higher hematologic events were infrequent and included neutropenia (16%), thrombocytopenia (11%), and anemia (10%). These impressive results led to its breakthrough designation for relapsed MCL. Results of phase III trials are eagerly awaited comparing ibrutinib versus temsirolimus in patients who relapsed and assessing a BR schedule with or withour ibrutinib in fırst line.
Another inhibitor of the BCR signal cascade, the specifıc PI3K inhibitor idelalisib achieved also a promising ORR of 62% in relapsed MCL patients, but duration of remission seem to be limited.
New monoclonal anti-CD20 antibodies, such as obinutuzumab and ofatumumab, are currently being investigated in clinical trials, but data in MCL are still limited. 40 Other intriguing approaches are the bispecifıc anti-CD19/anti-CD3 mAB, showing a high effıcacy particularly in MCL patients. 41 Two cell-cycle-targeted drugs, flavopiridol and PD0332991 (direct inhibitors of cyclin-dependent kinase 4 and 6), also showed activity in relapsed MCL alone and in combination with fludarabine, rituximab, or bortezomib. Finally, promising results have been recently reported for an oral secondgeneration BCL-2 specifıc BH3 mimetic ABT-199. 42 
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